StemRIM
Matters Concerning Business Plan and Growth Potential
Explains the business model for regenerative induction pharmaceuticals. Centered on collaboration with Osaka University and the Institute for Collaborative Research on Regenerative Induction Pharmaceuticals, the business model relies primarily on license-out income and milestone payments. For the fiscal year ending July 2026 there are no progress-based revenues, creating instability, but the company holds 5,370 million yen in cash and deposits as a funding outlook for 2027 onward and provides projected cash outflows for R&D and general administrative expenses.
Key Figures
- 53.7 hundred million yen: Cash and deposits balance
- 13〜17 hundred million yen: Projected cash outflows for R&D in 2027
- 2.3 hundred million yen〜3.1 hundred million yen: Projected cash outflows for general and administrative expenses in 2027
AI要約
Overview of Business Model and R&D Structure
The business model focuses on Osaka University-derived regenerative induction pharmaceuticals and licenses development, manufacturing, and sales rights to domestic and international pharmaceutical companies. Revenue sources include upfront payments at contract signing, milestone payments, royalty income, and joint research income. For the fiscal year ending July 2026, there were no progress-based revenues, highlighting challenges in revenue stability typical of a drug discovery venture.
Financial Position and Future Funding Plan
At period-end the company holds 53.7 hundred million yen in cash and deposits. Annual expenditure projections for the fiscal year ending July 2027 assume 13〜17 hundred million yen in R&D cash outflows and 2.3 hundred million yen〜3.1 hundred million yen in general and administrative cash outflows, aiming to secure funding for stable R&D activities through 2028. Currently, business-derived revenue is limited, so additional funding strategies are important to stabilize the revenue structure.
StemRIM
Company overview · Stock price · Financial data · All IR
